Indo-MIM Q1 EBITDA up 23% to ₹4,000 million; net profit surges 32%
Indo-MIM delivered strong Q1FY27 results with consolidated net profit rising 31.6% YoY to ₹2,401.2 million. Revenue grew 9.4% to ₹12,187.4 million. Key highlights include an EBITDA of ₹4,000 million with margins expanding to 33.36% from 29.33%, and a dividend declaration of ₹6.80 per share.

*this image is generated using AI for illustrative purposes only.
The Board of Directors of Indo-MIM approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, on August 17, 2026. The company reported a consolidated net profit of ₹2,401.2 million, up 31.6% year-on-year (YoY) from ₹1,824.1 million in Q1FY26. Standalone net profit stood at ₹2,231.7 million, rising 23.5% YoY from ₹1,807.4 million.
Consolidated revenue from operations increased 9.4% to ₹12,187.4 million from ₹11,141.0 million in the corresponding quarter of the previous fiscal. Standalone revenue grew 3.2% to ₹10,031.1 million from ₹9,720.5 million. The company also declared an aggregate dividend of ₹6.80 per equity share during the quarter, comprising a first interim dividend of ₹3.50 and a second interim dividend of ₹3.30.
Financial Performance Highlights
The following table outlines the key financial metrics for the quarter:
| Metric: | Q1FY27 (Consolidated) | Q1FY26 (Consolidated) | Change | Q1FY27 (Standalone) | Q1FY26 (Standalone) |
|---|---|---|---|---|---|
| Revenue from Operations: | ₹12,187.4 million | ₹11,141.0 million | +9.4% | ₹10,031.1 million | ₹9,720.5 million |
| Net Profit: | ₹2,401.2 million | ₹1,824.1 million | +31.6% | ₹2,231.7 million | ₹1,807.4 million |
| Earnings Per Share (Basic): | ₹4.96 | ₹3.78 | - | ₹4.61 | ₹3.75 |
| Other Income: | ₹32.1 million | ₹130.7 million | -75.4% | ₹27.3 million | ₹109.8 million |
Total comprehensive income for the consolidated group reached ₹2,430.2 million, compared to ₹1,856.7 million in Q1FY26. Standalone total comprehensive income was ₹2,278.0 million, up from ₹1,817.5 million in the prior year period.
What the Numbers Show
A notable divergence exists between operating performance and other income. While consolidated net profit surged 31.6% YoY, consolidated other income fell sharply by 75.4% to ₹32.1 million from ₹130.7 million in Q1FY26. This indicates that the profit growth was driven primarily by core operational improvements rather than non-operating gains, which had contributed significantly to profits in the prior year quarter.
Furthermore, the company’s operating leverage improved significantly. Consolidated EBITDA rose to ₹4,000 million from ₹3,260 million in Q1FY26, representing a 22.7% increase. This outpaced revenue growth of 9.4%, leading to an expansion in the EBITDA margin to 33.36% from 29.33% in the previous year. The margin expansion underscores improved cost efficiency and operational scale despite the decline in other income.
Corporate Actions and Governance
In addition to financial results, the board appointed M/s. SNM & Associates, Practicing Company Secretaries, as the Secretarial Auditor for a term of five consecutive financial years, from FY27 to FY31. This appointment is subject to member approval at the ensuing Annual General Meeting (AGM).
The board also ratified the Indo-MIM Employees Stock Option Plan, 2024 (ESOP 2024), pending shareholder approval at the AGM. Notice for the company’s 30th AGM for the financial year ended March 31, 2026, was also approved.
Suri & Co., Chartered Accountants, issued a limited review report on the unaudited financial statements, stating that nothing came to their attention to cause them to believe the statements were not prepared in accordance with Ind AS 34 or contained material misstatements.
Historical Stock Returns for Indo-MIM
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.61% | +14.64% | +13.51% | 0.0% | 0.0% | 0.0% |
Can the 33.36% EBITDA margin expansion be sustained in Q2FY27 given the normalization of other income?
How will the approval of the ESOP 2024 plan impact future earnings per share through potential dilution?
What specific operational cost-cutting measures or pricing strategies drove the 22.7% EBITDA growth despite only 9.4% revenue growth?



























